FibroBiologics to present preclinical and clinical data at ACTRIMS Forum

FibroBiologics will present in vitro and in vivo preclinical data using allogeneic human dermal fibroblasts, or HDFs, and HDF spheroids as well as primary safety phase 0/1 clinical trial data for the single-dose infusion of HDFs during the poster sessions at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis, or ACTRIMS, Forum 2024 on Thursday, February 29. “Our in vivo animal studies provided evidence that allogeneic HDFs are capable of suppressing pathogenic T cell activation, stimulating T regulatory cell expansion, inhibiting dendritic cell maturation, and stimulating oligodendrocyte expansion and myelin protein expression. Based on our results to date, we are enthusiastic about the promise of HDFs for the treatment of MS, although we understand that further study is required. In pursuit of that goal, FibroBiologics is designing a phase II clinical trial to study the safety and efficacy profile of various concentrations of HDF spheroids and the effect of multiple-dose treatments over an eighteen-month study period,” said Dr. Hamid Khoja, Chief Scientific Officer at FibroBiologics.